GAITHERSBURG, Md., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the status of its 2011 BioThrax® (Anthrax Vaccine Adsorbed) procurement contract and the status of its discussions with the Centers for Disease Control and Prevention (CDC) for a follow-on procurement contract for BioThrax.
2011 Procurement Contract
CDC has exercised an option to procure all remaining BioThrax doses, thereby committing to take delivery of the full 44.75 million doses, under the procurement contract announced on October 3, 2011 and due to expire September 30, 2016. In concert with this option exercise, CDC has granted a no-cost extension to enable delivery of the remaining doses to be completed by November 30, 2016.
Follow-On Procurement Contract
The company remains in active negotiations with CDC with respect to the Sole Source Notification (2016-N-17905) issued in June indicating CDC’s intention to award Emergent a contract for the purchase of 29.4 million doses of BioThrax over five years. The company will provide more clarity upon finalization of the contract.
BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA), is indicated for both pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease.
About Emergent BioSolutions
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the total potential realizable value of the contract, our strategy, future operations, prospects, plans and objectives with respect to BioThrax and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates” and similar expressions, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax procurement under the contract; CDC’s decisions to exercise options under the contract; and our manufacturing capabilities and strategies. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.
Robert G. Burrows
Vice President, Investor Relations
Tracey Schmitt Lintott
Senior Vice President, Global Public Affairs
Emergent BioSolutions Inc.